{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:17:29Z","timestamp":1783142249715,"version":"3.54.6"},"reference-count":30,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.5551\/jat.66030","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:10:38Z","timestamp":1775513438000},"page":"968-978","source":"Crossref","is-referenced-by-count":0,"title":["Switching from Conventional Fibrates to Pemafibrate Improves Lipid Profiles, Liver Enzymes, Renal Function, and Fibrosis Markers in Dyslipidemic Patients with MASLD: A Multicenter Real-World Study"],"prefix":"10.5551","volume":"33","author":[{"given":"Takao","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kiyooka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Atami hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, IUHW Narita hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015; 149: 389-397","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hadjivasilis A, Kouis P, Kousios A, Panayiotou A. The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies. J Clin Med, 2022; 11: 768","DOI":"10.3390\/jcm11030768"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate. Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Curr Atheroscler Rep, 2020; 22: 5","DOI":"10.1007\/s11883-020-0823-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kanno K, Koseki M, Chang J, Saga A, Inui H, Okada T, Tanaka K, Asaji M, Zhu Y, Ide S, Saito S, Higo T, Okuzaki D, Ohama T, Nishida M, Kamada Y, Ono M, Saibara T, Yamashita S, Sakata Y. Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. Sci Rep, 2022; 12: 2996","DOI":"10.1038\/s41598-022-06542-8"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, Yoneda M, Takizawa T, Saito S, Nagashima Y, Nakajima A. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep, 2017; 7: 42477 doi: 10.1038\/srep42477","DOI":"10.1038\/srep42477"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, Kitao S, Fujioka Y, Yamamoto K, Isomoto H. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Med, 2020; 63: 188-197","DOI":"10.33160\/yam.2020.08.009"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Tani J, Shi T, Himoto T, Tatsuta M, Moriya A, Senoo T, Tsutsui A, Nagano T, Takaguchi K, Ono M, Masaki T. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int, 2023; 17: 606-614","DOI":"10.1007\/s12072-022-10453-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Izumihara R, Nomoto H, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY, Nagai S, Sakuma I, Nakamura A, Atsumi T. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease. Diabetes Metab J, 2024; 48: 473-481","DOI":"10.4093\/dmj.2023.0370"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Miller M. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr Opin Cardiol, 2024; 39: 286-291","DOI":"10.1097\/HCO.0000000000001136"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-G\u00f3mez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023; 79: 1542-1556","DOI":"10.1097\/HEP.0000000000000520"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clin Chem, 2021; 67: 987-997","DOI":"10.1093\/clinchem\/hvab048"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes\u00e4niemi YA, Sullivan D, Hunt D, Colman P, d\u2019Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) de Lorgeril M, Salen P, Paillard F, Lacan P, Richard G. Lipid-lowering drugs and homocysteine. Lancet, 1999; 353: 209-210","DOI":"10.1016\/S0140-6736(05)77220-2"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Horinouchi Y, Murashima Y, Yamada Y, Yoshioka S, Fukushima K, Kure T, Sasaki N, Imanishi M, Fujino H, Tsuchiya K, Shinomiya K, Ikeda Y. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci, 2023; 321: 121590. doi: 10.1016\/j.lfs.2023.121590","DOI":"10.1016\/j.lfs.2023.121590"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M, Kondo M, Endo H. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study. J Atheroscler Thromb, 2023; 30: 443-454","DOI":"10.5551\/jat.63659"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T; K-877-04 Study Group. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016: 249: 36-43","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S. Effects of Pemafibrate, a Novel Selective PPAR\u03b1 Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 2018; 41: 538-546","DOI":"10.2337\/dc17-1589"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2021; 54: 1263-1277","DOI":"10.1111\/apt.16596"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sumida Y, Toyoda H, Yasuda S, Kimoto S, Sakamoto K, Nakade Y, Ito K, Osonoi T, Yoneda M. Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study. J Atheroscler Thromb, 2024; 31: 1620-1633","DOI":"10.5551\/jat.64896"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest, 2006; 116: 571-580","DOI":"10.1172\/JCI27989"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Karahashi M, Hoshina M, Yamazaki T, Sakamoto T, Mitsumoto A, Kawashima Y, Kudo N. Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats. J Pharmacol Sci, 2013; 123: 356-370","DOI":"10.1254\/jphs.13149FP"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron, 2002; 92: 536-541","DOI":"10.1159\/000064083"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Zingerman B, Ziv D, Feder Krengel N, Korzets A, Matok I. Cessation of Bezafibrate in patients with chronic kidney disease improves renal function. Sci Rep, 2020; 10: 19768","DOI":"10.1038\/s41598-020-76861-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S, Of The K-Study Group OB. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-\u03b1 Modulator (SPPARM\u03b1), in Dyslipidemic Patients with Renal Impairment. Int J Mol Sci, 2019; 20: 706","DOI":"10.3390\/ijms20030706"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Aomura D, Harada M, Yamada Y, Nakajima T, Hashimoto K, Tanaka N, Kamijo Y. Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism. Metabolites, 2021; 11: 372","DOI":"10.3390\/metabo11060372"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26) Tomohiro Kamimura, Neil Hounslow, Hideki Suganami, Ryohei Tanigawa. Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies. Clin Transl Sci, 2024; 17: e13900. doi: 10.1111\/cts.13900","DOI":"10.1111\/cts.13900"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Iwasaki M, Suzuki H, Umezawa Y, Koshida T, Saito M, Fukuda H, Takahara H, Matsuzaki K, Suzuki Y. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study. Medicine (Baltimore), 2023; 102: e32818","DOI":"10.1097\/MD.0000000000032818"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hirano T, Ito Y. The influence of triglycerides on small dense low-density lipoprotein cholesterol levels is attenuated in low low-density lipoprotein-cholesterol range: Implications for the negative results of the PROMINENT trial. J Diabetes Investig, 2023; 14: 902-906","DOI":"10.1111\/jdi.14013"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, P\u00e1ll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E. Effects of a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig, 2018; 9: 1323-1332","DOI":"10.1111\/jdi.12845"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/7\/33_66030\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:44:01Z","timestamp":1783140241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/7\/33_66030\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66030","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"66030"}}